Abstract Number: 1496 • 2014 ACR/ARHP Annual Meeting
Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout
Background/Purpose: Mavrilimumab is a recombinant human monoclonal antibody which neutralizes granulocyte-macrophage colony stimulating factor (GM-CSF) activity by selectively binding to the alpha subunit of its…Abstract Number: 272 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologics such as etanercept (ETN), approved in the UK in…